MedTrace Logo

Anakinra for Preterm Infants Pilot

NCT05280340 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2024-09-19

No results posted yet for this study

Summary

Phase I/II study of anakinra to prevent the impact of perinatal inflammation in extremely premature infants.

Conditions

Interventions

DRUG

Anakinra

Anakinra will be given to enrolled infants starting in the first 24hrs of life for the first 3 weeks of life.

Sponsors & Collaborators

  • Monash University

    collaborator OTHER

  • Hudson Institute of Medical Research

    collaborator UNKNOWN

  • Te Whatu Ora - Health New Zealand

    collaborator UNKNOWN

  • University of Auckland, New Zealand

    collaborator OTHER

  • Monash Medical Centre

    lead OTHER

Principal Investigators

  • Marcel Nold, Prof · Monash University

  • Claudia Nold, Prof · Hudson Institute of Medical Research

  • Rod Hunt, Prof · Monash University

  • Rob Galinsky, Dr · Hudson Institute of Medical Research

  • Gergely Toldi, Dr · Starship Children's Hospital, Te Whatu Ora - Health New Zealand

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
24 Weeks
Max Age
28 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2024-03-21
Completion
2025-03-31

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05280340 on ClinicalTrials.gov